Abstract

PurposeTo present our experience in prostatic transrectal ultrasound and transrectal ultrasound-guided biopsy over a ten-year period by a retrospective analysis in order to determine the detection rate of adenocarcinoma, identify the distribution of positive samples in the gland, and evaluate the usefulness of biopsy of nodules seen on imaging studies. Materials and methodsA total of 1163 ultrasound and ultrasound-guided transrectal prostate biopsies were performed between March 2001 and November 2011. The population sample included patients who had more than one biopsy performed. Data obtained from these procedures enables us to identify three age groups according to the incidence of pathology, to determine the most frequent location of adenocarcinoma within the prostate, and to evaluate the usefulness of prostate nodules biopsy in the detection of adenocarcinoma. ResultsThe data analysis showed a 16% detection rate of adenocarcinoma in men under 50 years of age, 36% in patients between 50 and 65 years, and 48% in patients older than 65 years. The left base of the prostate had the highest detection rate (15%), followed by left medium (14%), right base (14%), right medium (13%), left apex (12%), left lateral medium (12%), right apex (11%) and right lateral medium (10%).Nodular images were found in 299 patients: 118 were positive for adenocarcinoma (Group A) and 181 were negative (Group B). Group A was divided into 3 subgroups: Subgroup A, with a positive result only in the nodule sample, and a negative result in the rest of the gland sample; Subgroup B, with a positive result in the gland samples but negative in the nodule sample; and Subgroup C, with results that were positive both in the gland and nodule samples. ConclusionUltrasound and ultrasound-guided transrectal prostate biopsy play an important role in the evaluation of the prostate when adenocarcinoma is suspected. Based on our experience, ultrasound-guided prostate biopsy is the most useful method for the detection of adenocarcinoma, especially in patients older than 65 years of age, and the nodule sample (if any) should be included in the eight-biopsy scheme.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call